Research output per year
Research output per year
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Profiles
-
Activity of STAMP inhibitors in ABL2 rearranged acute lymphoblastic leukemia is dependent on the Abl2 SH3 domain
Lagonik, E., Page, E. C., Bruning, J. B., Eadie, L. N., Heatley, S. L., Greenwood, M., Fong, C. Y., Moore, A. S., Yeung, D. T., Hughes, T. P. & White, D. L., Aug 2025, In: Blood Neoplasia. 2, 3, 100109.Research output: Contribution to journal › Article › peer-review
Open Access1 Citation (Scopus) -
Asciminib for Philadelphia chromosome-positive leukemias
Hughes, T. P., White, D. L. & Yeung, D. T., 26 Jun 2025, In: Haematologica. 110, 10, p. 2273-2280 8 p.Research output: Contribution to journal › Review article › peer-review
Open Access -
Disease-specific survival for people with chronic myeloid leukaemia, South Australia, 1980–2020: a retrospective cohort study
Beckmann, K., Kearney, B. J., Shanmuganathan, N., Yeung, D. & Hughes, T., 8 Dec 2025, In: Medical Journal of Australia. 223, 11, p. 643-645 3 p.Research output: Contribution to journal › Article › peer-review
Prizes
-
-
American Society of Hematology (ASH) International Post-doctoral Fellow (IPDF) approval and $500 ASH Abstract Achievement Award
Pagani, I. (Recipient) & Pagani, I. (Recipient), 2013
Prize
-
Activities
-
Debate 1 – CML - Asciminib first line?
Hughes, T. (Invited speaker)
7 Mar 2025 → 9 Mar 2025Activity: Invited talks and oral presentations › Invited Keynote and Plenary Presentations
-
New discoveries that will shape future therapies in Chronic Myeloid Leukemia
Hughes, T. (Speaker)
2 Mar 2025 → 29 Mar 2025Activity: Invited talks and oral presentations › Invited Keynote and Plenary Presentations
-
'Embarking on a new journey with Scemblix’ Meeting
Hughes, T. (Speaker)
23 Apr 2025Activity: Invited talks and oral presentations › Invited Keynote and Plenary Presentations